Tatva Chintan Pharma Chem Ltd. Presents Q3 FY26 Investor Presentation
Tatva Chintan Pharma Chem Ltd. reported strong Q3 FY26 results. Revenue grew 53% YoY to ₹131.3 crore. PAT surged 10,889% YoY to ₹15.2 crore. For 9MFY26, revenue increased 35% YoY to ₹371.7 crore, and PAT grew 578% YoY to ₹31.7 crore. The company highlighted its diversified product portfolio and international presence.
The substantial increase in key financial metrics like revenue and profit, along with the release of an investor presentation detailing future strategies and performance, is likely to have a significant impact on investor perception and the company's stock.
The company reported significant year-on-year growth in revenue, EBITDA, and PAT for both the quarter and nine months ended December 31, 2025, indicating strong financial performance.
Tatva Chintan Pharma Chem Limited (TCPCL) has released its Investor Presentation for the quarter and nine months ended 31 December 2025. The presentation details the company's financial performance, operational highlights, and strategic outlook.
For the nine months ended 31 December 2025 (9MFY26), TCPCL reported a significant year-on-year (YoY) growth in revenue from operations, which increased by 35% to ₹3,717 million (₹371.7 crore) from ₹2,749 million (₹274.9 crore) in 9MFY25. EBITDA (excluding other income) saw a substantial YoY increase of 154%, reaching ₹650 million (₹65 crore) from ₹256 million (₹25.6 crore), with the EBITDA margin improving to 17% from 9%. Profit After Tax (PAT) surged by 578% YoY to ₹317 million (₹31.7 crore) from ₹47 million (₹4.7 crore), and the PAT margin improved to 9% from 2%.
In the third quarter of FY26 (Q3FY26), revenue from operations grew by 53% YoY to ₹1,313 million (₹131.3 crore) from ₹859 million (₹85.9 crore) in Q3FY25. EBITDA (excluding other income) increased by 261% YoY to ₹255 million (₹25.5 crore) from ₹71 million (₹7.1 crore), with the EBITDA margin expanding to 19% from 8%. PAT saw a remarkable YoY increase of 10,889%, reaching ₹152 million (₹15.2 crore) from ₹1 million (₹0.1 crore), and the PAT margin improved to 12% from 0%.
The presentation also highlights the company's product categories, including Phase Transfer Catalyst (PTC), Structure Directing Agents (SDA), Electrolyte Salts (ESS), and Pharma & Agrochemical Intermediates (PASC). TCPCL emphasizes its commitment to sustainable practices and cutting-edge technology, including its pioneering work in electrolysis and continuous flow chemistry. The company has an expansive international presence, serving customers in over 25 countries, with exports constituting 62% of its revenue in FY25. Tatva Chintan Pharma Chem Limited is also a leading manufacturer in its key product segments, with a diversified product portfolio that reduces dependence on any single industry.
What to do with a filing like this
Tatva Chintan Pharma Chem Limited filed this with the NSE as a statutory disclosure, categorised under other company updates. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Tatva Chintan Pharma Chem Limited. Read the original for the full detail.